HomeAbout

TL;DR CNBC


Moderna says FDA delayed RSV vaccine approval to end of May - TL;DR CNBC

Moderna says FDA delayed RSV vaccine approval to end of May

Publishing timestamp: 2024-05-10 07:00:01


Summary

Moderna's vaccine for respiratory syncytial virus approval by FDA delayed to end of May due to administrative constraints. Investors are closely watching as it would be the company's second product to launch in the U.S. after its Covid vaccine. Approval would showcase the versatility of Moderna's mRNA platform beyond treating Covid.


Sentiment: NEUTRAL

Tickers: PFEGSKGSK-GBMRNA

Keywords: health care industrypfizer incfdabusinessbiotech and pharmaceuticalsbiotechnologybreaking newspharmaceuticalsmoderna incbusiness newsgsk plc

Source: https://www.cnbc.com/2024/05/10/moderna-says-rsv-vaccine-fda-approval-delayed-to-end-of-may.html


Developed by Leo Phan